Amer A. Beg

19.4k total citations · 7 hit papers
95 papers, 16.4k citations indexed

About

Amer A. Beg is a scholar working on Immunology, Cancer Research and Molecular Biology. According to data from OpenAlex, Amer A. Beg has authored 95 papers receiving a total of 16.4k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Immunology, 47 papers in Cancer Research and 44 papers in Molecular Biology. Recurrent topics in Amer A. Beg's work include NF-κB Signaling Pathways (43 papers), Immune Response and Inflammation (33 papers) and interferon and immune responses (13 papers). Amer A. Beg is often cited by papers focused on NF-κB Signaling Pathways (43 papers), Immune Response and Inflammation (33 papers) and interferon and immune responses (13 papers). Amer A. Beg collaborates with scholars based in United States, China and Australia. Amer A. Beg's co-authors include David Baltimore, Albert S. Baldwin, A S Baldwin, Timothy S. Finco, William C. Sha, Sankar Ghosh, Roderick T. Bronson, Pascale V. Nantermet, Ming O. Li and Ye Zheng and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Amer A. Beg

92 papers receiving 16.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death

1996 2.7k citations Amer A. Beg, David Baltimore profile →
Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB

1995 1.6k citations Amer A. Beg, Sankar Ghosh et al. Nature profile →
Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation.

1993 944 citations Amer A. Beg, Timothy S. Finco et al. Molecular and Cellular Biology profile →
The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors.

1993 709 citations Amer A. Beg, A S Baldwin Genes & Development profile →
Characterization of an immediate-early gene induced in adherent monocytes that encodes IκB-like activity

1991 677 citations Amer A. Beg, Albert S. Baldwin et al. profile →
I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention.

1992 655 citations Amer A. Beg, A S Baldwin et al. Genes & Development profile →
ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis

2022 262 citations Ting Zhang, Chaoran Yin et al. Nature profile →

Peers

Countries citing papers authored by Amer A. Beg

Since Specialization

Citations

This map shows the geographic impact of Amer A. Beg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amer A. Beg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amer A. Beg more than expected).

Fields of papers citing papers by Amer A. Beg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amer A. Beg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amer A. Beg. The network helps show where Amer A. Beg may publish in the future.

Co-authorship network of co-authors of Amer A. Beg

This figure shows the co-authorship network connecting the top 25 collaborators of Amer A. Beg. A scholar is included among the top collaborators of Amer A. Beg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amer A. Beg. Amer A. Beg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sequestration of the phagocyte metabolite itaconate by Pseudomonas aeruginosa RpoN promotes successful pulmonary infection 2025 ·Nature Communications ·Amer A. Beg, Zihua Liu, (unknown), (unknown), (unknown), Joseph E. Miller, (unknown), Lars E. P. Dietrich, Chu Wang, Ian A. Lewis, Tania Wong Fok Lung, (unknown), Alice Prince	0
2	Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer 2024 ·Neoplasia ·(unknown), Regina S. Whitaker, (unknown), Shonagh Russell, (unknown), Justin Pollara, Kyle C. Strickland, Mark J. Cantwell, Amer A. Beg, Andrew Berchuck, Scott Antonia, Rebecca A. Previs	5
3	Histone Deacetylase Inhibitors Directly Modulate T Cell Gene Expression and Signaling and Promote Development of Effector-Exhausted T Cells in Murine Tumors 2024 ·The Journal of Immunology ·(unknown), Hong Zheng, (unknown), (unknown), (unknown), Xiaoqing Yu, Amer A. Beg	12
4	Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results. 2023 ·Journal of Clinical Oncology ·Andreas Saltos, Tawee Tanvetyanon, Ben Creelan, Michael Shafique, Scott Antonia, Eric B. Haura, Hong Zheng, Xiaoqing Yu, James J. Saller, (unknown), Ram Thapa, Theresa A. Boyle, Dung‐Tsa Chen, Amer A. Beg, Jhanelle E. Gray	2
5	Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity 2023 ·Cancer Immunology Research ·(unknown), Xiaoqing Yu, (unknown), (unknown), Mengyu Xie, Joseph Johnson, Theresa A. Boyle, Brian Ruffell, Bradford A. Perez, (unknown), Neal Ready, Andreas Saltos, Mark J. Cantwell, Amer A. Beg	9
6	Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer 2022 ·Clinical Cancer Research ·Alberto Chiappori, Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa, (unknown), Zhihua Chen, (unknown), Amer A. Beg, Theresa A. Boyle, (unknown), (unknown), Erick J. Morris, Mehreteab Aregay, Felipe K. Hurtado, Luigi Manenti, Scott Antonia	50
7	ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis breakdown → 2022 ·Nature ·Ting Zhang, Chaoran Yin, А. И. Федоров, Liangjun Qiao, Hong‐Liang Bao, Nazar Beknazarov, Shiyu Wang, Avishekh Gautam, Riley Williams, Jeremy Chase Crawford, Suraj Peri, Vasily M. Studitsky, Amer A. Beg, Paul G. Thomas, Carl R. Walkley, Yan Xu, Maria Poptsova, Alan Herbert, Siddharth Balachandran	262
8	Mistic: An open-source multiplexed image t-SNE viewer 2022 ·Patterns ·Sandhya Prabhakaran, Chandler Gatenbee, Mark Robertson‐Tessi, Jeffrey West, Amer A. Beg, Jhanelle E. Gray, Scott Antonia, Robert A. Gatenby, Alexander R.A. Anderson	0
9	Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer 2021 ·PLoS ONE ·Dung‐Tsa Chen, Wenyaw Chan, Zachary Thompson, Ram Thapa, Amer A. Beg, Andreas Saltos, Alberto Chiappori, Jhanelle E. Gray, Eric B. Haura, Trevor Rose, Ben Creelan	4
10	Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer 2019 ·Clinical Cancer Research ·Jhanelle E. Gray, Andreas Saltos, Tawee Tanvetyanon, Eric B. Haura, Ben Creelan, Scott Antonia, Michael Shafique, Hong Zheng, Wenjie Dai, James J. Saller, Zhihua Chen, Nishan Tchekmedyian, (unknown), Ram Thapa, Theresa A. Boyle, Dung‐Tsa Chen, Amer A. Beg	104
11	HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma 2016 ·Clinical Cancer Research ·Hong Zheng, Weipeng Zhao, Cihui Yan, (unknown), Michael T. Massengill, Mengyu Xie, (unknown), David Noyes, Gary V. Martinez, Roha Afzal, Zhihua Chen, Xiubao Ren, Scott Antonia, Eric B. Haura, Brian Ruffell, Amer A. Beg	264
12	Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma 2009 ·Cancer Research ·Danielle N. Yarde, Vasco Oliveira, Linda Mathews, Xingyu Wang, Alejandro Villagra, David Boulware, Kenneth H. Shain, Lori Hazlehurst, Melissa Alsina, Dung‐Tsa Chen, Amer A. Beg, William S. Dalton	90
13	Mechanism of All- Trans Retinoic Acid Effect on Tumor-Associated Myeloid-Derived Suppressor Cells 2007 ·Cancer Research ·Yulia Nefedova, Mayer Fishman, Simon Sherman, Xingyu Wang, Amer A. Beg, Dmitry I. Gabrilovich	347
14	Interplay of IKK/NF-κB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy 2007 ·Journal of Clinical Investigation ·Swarnali Acharyya, S. Armando Villalta, Nadine Bakkar, Tepmanas Bupha‐Intr, Paul M.L. Janssen, (unknown), Zhi-Wei Li, Amer A. Beg, Sankar Ghosh, Zarife Sahenk, Michael Weinstein, (unknown), Jill A. Rafael‐Fortney, Michael Karin, James G. Tidball, Albert S. Baldwin, Denis C. Guttridge	366
15	Activation of Dendritic Cells via Inhibition of Jak2/STAT3 Signaling 2005 ·The Journal of Immunology ·Yulia Nefedova, Pingyan Cheng, Daniele M. Gilkes, Michelle A. Blaskovich, Amer A. Beg, Saı̈d M. Sebti, Dmitry I. Gabrilovich	164
16	Regulation of α-Fetoprotein by Nuclear Factor-κB Protects Hepatocytes from Tumor Necrosis Factor-α Cytotoxicity during Fetal Liver Development and Hepatic Oncogenesis 2004 ·Cancer Research ·Lakita G. Cavin, Venkatraman Manickam, Valentina M. Factor, Swayamjot Kaur, Insa S. Schroeder, Frank Mercurio, Amer A. Beg, Snorri S. Thorgeirsson, Marcello Arsura	32
17	Targeted Mutation of TNF Receptor I Rescues the RelA-Deficient Mouse and Reveals a Critical Role for NF-κB in Leukocyte Recruitment 2001 ·The Journal of Immunology ·Elizabeth Alcamo, Joseph P. Mizgerd, Bruce Horwitz, Rod T. Bronson, Amer A. Beg, Martin Scott, Claire M. Doerschuk, Richard O. Hynes, David Baltimore	206
18	The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. breakdown → 1993 ·Genes & Development ·Amer A. Beg, A S Baldwin	709
19	Tumor Necrosis Factor and Interleukin-1 Lead to Phosphorylation and Loss of IκBα: a Mechanism for NF-κB Activation 1993 ·Molecular and Cellular Biology ·Amer A. Beg, Timothy S. Finco, Pascale V. Nantermet, Albert S. Baldwin	225
20	Induction of NF-κB DNA-Binding Activity during the G ₀ -to-G ₁ Transition in Mouse Fibroblasts 1991 ·Molecular and Cellular Biology ·Albert S. Baldwin, Jane Clifford Azizkhan, David E. Jensen, Amer A. Beg, (unknown)	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact